Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.
Evens AM, Spies WG, Helenowski IB, Patton D, Spies S, Jovanovic BD, Miyata S, Hamilton E, Variakojis D, Chen J, Naumovski L, Rosen ST, Winter JN, Miller RA, Gordon LI. Evens AM, et al. Clin Cancer Res. 2009 Oct 15;15(20):6462-71. doi: 10.1158/1078-0432.CCR-09-0905. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825958 Free PMC article. Clinical Trial.
Burkitt's and Burkitt-like lymphoma.
Evens AM, Gordon LI. Evens AM, et al. Curr Treat Options Oncol. 2002 Aug;3(4):291-305. doi: 10.1007/s11864-002-0029-9. Curr Treat Options Oncol. 2002. PMID: 12074766 Review.
Treatment of T-cell non-Hodgkin's lymphoma.
Evens AM, Gartenhaus RB. Evens AM, et al. Curr Treat Options Oncol. 2004 Aug;5(4):289-303. doi: 10.1007/s11864-004-0020-8. Curr Treat Options Oncol. 2004. PMID: 15233906 Review.
248 results